监测策略对消融成功率和消融后房颤负荷评估的影响
基于CIRCA-DOSE试验346例患者的节律史重建,通过计算机模拟评估不同无创间歇监测策略对房颤消融后复发检测的敏感性及房颤负荷估算的准确性。结果显示多数试验所用监测策略敏感性低,串行3次14天心电图监测的敏感度为64.6%,与植入式心脏监测器(ICM)的房颤负荷相关性R²=0.85、ICC=0.91;ICM在心律失常检测上优于间歇监测,应作为临床试验的金标准。
要点
- 消融后房颤复发率高度依赖监测策略,不同试验结果差异可能反映监测方案不同。
- 串行3次24/48小时心电图监测敏感性仅15.8%/24.5%,显著漏诊复发。
- 串行3次14天心电图监测累积至少28天/年,房颤负荷估算与ICM可比。
核心结论
- 消融后房性快速性心律失常复发率高度依赖所采用的监测策略,不同试验间的结果差异可能反映监测方案不同。
- 基于一致性指标,串行长期(7-14天)间歇监测每年累积至少28天监测,提供的房颤负荷估计与ICM可比。
- ICM在心律失常检测上优于间歇监测,应被视为临床试验的金标准。
研究设计与样本
- 基于CIRCA-DOSE试验(冷冻球囊对比接触力灌注射频导管消融)中346例患者的节律史进行重建。
- 采用计算机模拟评估一系列无创监测策略的免事件生存率、敏感性、阴性预测值和房颤负荷,包括当代房颤消融试验所用策略。
- 共分析126 290个监测日。
主要发现
- 12个月时,164例患者经ICM记录到房性心律失常复发(1年免事件生存率52.6%)。
- 多数房颤消融试验所用无创监测策略对心律失常复发的检测敏感性较差。
- 串行3次短时程监测(24/48小时心电图)漏诊相当比例复发,敏感性分别为15.8%(95%CI 8.9%-20.7%)和24.5%(95%CI 16.2%-30.6%)。
- 串行3次较长时程监测(14天心电图)更接近金标准ICM(敏感性64.6%,95%CI 53.6%-74.3%)。
- 短时程监测衍生的房颤负荷在复发患者中显著高估真实房颤负荷;串行3次14天心电图监测与ICM的房颤负荷相关性R²=0.85、组内相关系数=0.91。
关键数值与推荐
- 串行3次24小时心电图监测敏感性15.8%(95%CI 8.9%-20.7%)。
- 串行3次48小时心电图监测敏感性24.5%(95%CI 16.2%-30.6%)。
- 串行3次14天心电图监测敏感性64.6%(95%CI 53.6%-74.3%),与ICM房颤负荷R²=0.85、ICC=0.91。
- 串行长期(7-14天)间歇监测每年累积至少28天监测,房颤负荷估计与ICM可比。
临床怎么用
- 临床评估消融后房颤复发时需考虑监测策略对检出率的显著影响,避免因监测不足低估复发。
- 若采用间歇监测,优先选择串行长期(7-14天)监测并每年累积至少28天,以更准确估算房颤负荷。
- 临床试验中建议将ICM作为心律失常检测的金标准,间歇监测可用于负荷估算但检测敏感性较低。
局限性
- 研究基于CIRCA-DOSE试验患者节律史的计算机模拟重建,非前瞻性直接比较不同监测策略。
- 原文未报告模拟模型的具体假设、外部验证及对不同人群的普适性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various noninvasive intermittent rhythm monitoring strategies have been used to assess arrhythmia recurrences in trials evaluating pharmacological and invasive therapeutic interventions for atrial fibrillation (AF). We determined whether a frequency and duration of noninvasive rhythm monitoring could be identified that accurately detects arrhythmia recurrences and approximates the AF burden derived from continuous monitoring using an implantable cardiac monitor (ICM). METHODS: The rhythm history of 346 patients enrolled in the CIRCA-DOSE trial (Cryoballoon Versus Contact-Force Irrigated Radiofrequency Catheter Ablation) was reconstructed. Using computer simulations, we evaluated event-free survival, sensitivity, negative predictive value, and AF burden of a range of noninvasive monitoring strategies, including those used in contemporary AF ablation trials. RESULTS: A total of 126 290 monitoring days were included in the analysis. At 12 months, 164 patients experienced atrial arrhythmia recurrence as documented by the ICM (1-year event-free survival, 52.6%). Most noninvasive monitoring strategies used in AF ablation trials had poor sensitivity for detecting arrhythmia recurrence. Sensitivity increased with the intensity of monitoring, with serial (3) short-duration monitors (24-/48-hour ECG monitors) missing a substantial proportion of recurrences (sensitivity, 15.8% [95% CI, 8.9%-20.7%] and 24.5% [95% CI, 16.2%-30.6%], respectively). Serial (3) longer-term monitors (14-day ECG monitors) more closely approximated the gold standard ICM (sensitivity, 64.6% [95% CI, 53.6%-74.3%]). AF burden derived from short-duration monitors significantly overestimated the true AF burden in patients with recurrences. Increasing monitoring duration resulted in improved correlation and concordance between noninvasive estimates of the invasive AF burden (R2 = 0.85 and interclass correlation coefficient = 0.91 for serial [3] 14-day ECG monitors versus ICM). CONCLUSIONS: The observed rate of postablation atrial tachyarrhythmia recurrence is highly dependent on the arrhythmia monitoring strategy employed. Between-trial discrepancies in outcomes may reflect different monitoring protocols. On the basis of measures of agreement, serial long-term (7-14 day) intermittent monitors accumulating at least 28 days of annual monitoring provide estimates of AF burden comparable with ICM. However, ICMs outperform intermittent monitoring for arrhythmia detection, and should be considered the gold standard for clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01913522.
引用
- Aguilar M, Macle L, Deyell MW, et al. Influence of Monitoring Strategy on Assessment of Ablation Success and Postablation Atrial Fibrillation Burden Assessment: Implications for Practice and Clinical Trial Design. Circulation. 2021. PMID: 34816727. doi:10.1161/CIRCULATIONAHA.121.056109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。